Femasys, Inc. FEMY 深 沪
等待开盘 07-01 09:30:00 美东时间
4.18
+0.440
+11.76%
华盛通- 最 高4.284
- 今 开3.74
- 成交量 3.96万股
- 最 低 3.64
- 昨 收 3.74
- 总市值 1262.17万
- 52周最高 22.20
- 市盈率 静 --
- 换手率 1.31%
- 52周最低 3.50
- 委 比 -97.46%
- 总股本 301.95万
- 历史最高 275.00
- 量 比 1.04
- 振 幅 17.22%
- 历史最低 3.64
- 每 手 1
- 风险率 4.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Femasys Announces CE Mark Approval For FemHSG Catheter, Further Expanding Its Portfolio In Europe Through Commercial Partners
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for
05-13 21:05
Femasys Announces First Revenue-Generating Commercial Use Of Its Fertility Portfolio In An OBGYN Setting, Led By FemaSeed As A First-Line Infertility Treatment
The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and
05-05 21:15
Femasys Collaborates With AMI Technologies To Roll Out, Commercialize Fertility Portfolio In Israel
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today a strategic
04-16 21:03
Femasys Appoints John Canning COO
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of
04-01 21:03
Femasys Q4 EPS $(0.06) Beats $(0.12) Estimate, Sales $813.387K Miss $1.450M Estimate
Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.12) by 47.83 percent. This is a 73.91 percent increase over losses of $(0.23) per share from the same
04-01 05:10
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Lake Street Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $1.5
Lake Street analyst Benjamin Haynor initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating and announces Price Target of $1.5.
03-04 01:59
Femasys Secures American Medical Association CPT Editorial Panel Approval For Category III CPT Code Covering Use Of FemaSeed For Intratubal Insemination
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment --ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making
02-23 22:10
Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution
02-03 22:16
